The Study of Vidicizumab Combined With Tirelizumab in the Treatment of Breast Cancer With Low HER2 Expression
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Neoadjuvant Therapy
Interventions: DRUG: Disitamab Vedotin combined with Tislelizumab
Sponsor: Wuhan Union Hospital, China